⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89836 | 0.82 | — | — | |
| SCHEMBL29521347 | 0.72 | DYRK1A (0.47) | — | |
| Benzo[D]Oxazole SCHEMBL8888913 | 0.71 | NPC1 (0.39) | — | |
| SCHEMBL16576784 | 0.71 | MTNR1A (0.37) | — | |
| Benzo[D]Oxazole SCHEMBL27844655 | 0.69 | NPC1 (0.43) | — | |
| Benzo[D]Oxazole SCHEMBL7903 | 0.69 | — | — | |
| Benzo[D]Oxazole SCHEMBL2724328 | 0.69 | — | — | |
| SCHEMBL210197 | 0.69 | — | — | |
| Benzo[D]Oxazole SCHEMBL2385440 | 0.69 | NPC1 (0.43) | — | |
| Benzo[D]Oxazole SCHEMBL34464660 | 0.68 | NPC1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 881 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024083237-A1 | SUBSTITUTED HETEROARYL BICYCLIC COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2024-04-25 | — | — | WO | claimed |
| WO-2024059745-A2 | N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) ANTAGONISTS AND USES THEREOF | BEXSON BIOMEDICAL, INC. (US) | 2024-03-21 | — | — | WO | claimed |
| US-11891388-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2024-02-06 | — | — | US | claimed |
| US-20220227752-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2022-07-21 | — | — | US | claimed |
| US-11242343-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2022-02-08 | — | — | US | claimed |
| US-7935824-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-03 | — | — | US | claimed |
| WO-2000078726-A1 | IMIDAZOLINE DERIVATIVES FOR THE TREATMENT OF DIABETES, ESPECIALLY TYPE II DIABETES | ELI LILLY AND COMPANY (US) | 2000-12-28 | — | — | WO | claimed |
| US-4505840-A | Heterocyclic electroactive polymers | CHEVRON RESEARCH COMPANY (US) | 1985-03-19 | — | — | US | claimed |
| CN-113679717-B | Methods for inhibiting fascin | 康奈尔大学 | 2026-05-22 | — | — | CN | disclosed |
| US-20260124177-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | NOVITA PHARMACEUTICALS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4735420-A1 | ARYL INDOL-3-YL KETONE AND ARYL INDAZOL-3-YL KETONE INHIBITORS OF KIF18A | Volastra Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4727548-A1 | METHOD OF TREATING CANCER WITH INDOLINE INHIBITORS OF KIF18A | Volastra Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260098018-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12508245-B2 | Co-therapies including a metastasis inhibitor | NOVITA PHARMACEUTICALS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-4940718-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| US-4902707-A | Bicyclic pyrazolidinones, compositions and use | ELI LILLY AND COMPANY (US) | 1990-02-20 | — | — | US | disclosed |
| EP-0327239-A1 | 1-carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1989-08-09 | — | — | EP | disclosed |
| EP-0203722-A1 | Bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0202046-A1 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
| US-4505840-A | Heterocyclic electroactive polymers | CHEVRON RESEARCH COMPANY (US) | 1985-03-19 | — | — | US | disclosed |